Every SEC Form 3/4/5 on record for this filer (CIK 1309702) — 6 issuers, 71 transactions. Section-16 filings only: what they filed, not a biography, and titles are as filed on their latest form at each issuer.
| Ticker | Company | Role as filed | On file | Forms | Open-market net |
|---|---|---|---|---|---|
| NKTX | Nkarta, Inc. | Chief Executive Officer · Director | 2020-07-09 → 2026-06-22 | 23 | −$2M |
| ENGN | enGene Therapeutics Inc. | Director | 2024-05-17 → 2026-06-17 | 4 | — |
| PCRX | Pacira BioSciences, Inc. | Director · lapsed | 2015-08-19 → 2024-06-13 | 21 | −$1M |
| PRTO | PROTEON THERAPEUTICS INC | Director · lapsed | 2016-10-20 → 2018-06-11 | 4 | — |
| OMED | OncoMed Pharmaceuticals Inc | Chairman & CEO · lapsed | 2015-12-29 → 2017-10-12 | 9 | −$474,943 |
| RLYP | Relypsa Inc | Director · lapsed | 2016-06-08 → 2016-09-02 | 3 | −$19,571 |
| Ticker | Date | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| NKTX | 2026-06-18 | Sell | 1,776 | $2.71 | $4,813 | 390,247 |
| NKTX | 2026-01-15 | Sell | 26,046 | $2.07 | $53,915 | 390,023 |
| NKTX | 2025-06-18 | Sell | 1,790 | $1.79 | $3,204 | 320,069 |
| NKTX | 2025-01-15 | Sell | 17,378 | $2.20 | $38,232 | 319,859 |
| NKTX | 2024-06-18 | Sell | 1,770 | $5.60 | $9,912 | 240,737 |
| PCRX | 2024-06-13 | Sell | 880 | $28.38 | $24,974 | 12,724 |
3 of 6 issuers are covered and open a security page; the rest are on file here only.